ESMO 2022 | The evolving treatment paradigm for BRAF V600E-mutant mCRC

Sebastian Stintzing, MD, Charite University Hospital, Berlin, Germany, describes the current and future treatment options for patients with microsatellite instability (MSI)-high BRAF V600E-mutant metastatic colorectal cancer (mCRC). Trials are currently underway to assess cetuximab with EFGR antibodies and the Phase III BREAKWATER trial (NCT04607421) assess encorafenib, a BRAF inhibitor, with cetuximab. Prof. Stintzing additionally highlights research elucidating mechanisms of resistance to current treatments. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.